Chapter 44 Small Molecule Inhibitors of the PI3-Kinase Family

Chapter 53 Structural effects of oncogenic PI3Kα mutations.

Chapter 54 Clinical development of phosphatidylinositol-3 kinase pathway inhibitors.

Chapter 60 From the Bench to the Bed Side: PI3K Pathway Inhibitors in Clinical Development

Chapter 62 Faithfull Modeling of PTEN Loss Driven Diseases in the Mouse

Chapter 64 New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)

Chapter 65 PI3K: from the bench to the clinic and back.

Chapter 66 AKT Signaling in Physiology and Disease

Chapter 67 Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

Chapter 68 Oncogenic mutations of PIK3CA in human cancers.

Chapter 71 PI3K as a Target for Therapy in Haematological Malignancies

Chapter 80 Phosphatidylinositol 3-kinase: the oncoprotein.